| ID | 1184 |
| Name of the vaccine | SP093 |
| Microbe | Bacteria |
| Disease name | Salmonellosis |
| Name of bacteria | Salmonella enteritis |
| Type of vaccine | Polysaccharide |
| Nucleic acid content | Circular DNA |
| Age | 2 years and above |
| Description of the vaccine | Typhoid Vi Polysaccharide vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | Japan |
| Year of manufacture | 2012 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Gram-negative rod-shaped enterobacterium. |
| Efficacy | NA |
| Vaccine formulation | Solution for injection |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | Anti-Vi antibodies. |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For typhoid fever and bacterial infections. |
| Side effects of vaccine | Pain, erythema, swelling, fever, headache, malaise and myalgia. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01608815 |
| Reference | https://www.ncbi.nlm.nih.gov/nuccore/CP032851 |
| Other name | NA |
| Additional Links | https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005195-22/results
|